Genetic variants in the adenosine triphosphate-binding cassette subfamily B member 4 (ABCB4) gene, which encodes hepatocanonical phosphatidylcholine floppase, can lead to different phenotypes, such as progressive familial intrahepatic cholestasis (PFIC) type 3, low phospholipid-associated cholelithiasis, and intrahepatic cholestasis of pregnancy. The aim of this multicenter project was to collect information on onset and progression of this entity in different age groups and to assess the relevance of this disease for the differential diagnosis of chronic liver disease. Clinical and laboratory data of 38 patients (17 males, 21 females, from 29 families) with homozygous or (compound) heterozygous ABCB4 mutations were retrospectively collected. For further analysis, patients were grouped according to the age at clinical diagnosis of ABCB4-associated liver disease into younger age (<18 years) or adult age (≥18 years). All 26 patients diagnosed in childhood presented with pruritus (median age 1 year). Hepatomegaly and splenomegaly were present in 85% and 96% of these patients, respectively, followed by jaundice (62%) and portal hypertension (69%). Initial symptoms preceded diagnosis by 1 year, and 13 patients received a liver transplant (median age 6.9 years). Of note, 9 patients were misdiagnosed as biliary atresia, Alagille syndrome, or PFIC type 1. In the 12 patients with diagnosis in adulthood, the clinical phenotype was generally less severe, including intrahepatic cholestasis of pregnancy, low phospholipid-associated cholelithiasis, or (non)cirrhotic PFIC3. Conclusion: ABCB4 deficiency with onset in younger patients caused a more severe PFIC type 3 phenotype with the need for liver transplantation in half the children. Patients with milder phenotypes are often not diagnosed before adulthood. One third of the children with PFIC type 3 were initially misdiagnosed, indicating the need for better diagnostic tools and medical education. (Hepatology Communications 2018;2:504-514)
γ-glutamyltransferase (GGT) activity is elevated in ABCB4 disease.

To date, about 200 patients with ABCB4-associated liver disease have been described in the literature, mostly in smaller case reports (Table 1). Historically, patients with familial cholestasis and high GGT were depicted to have a PFIC3 phenotype leading to liver fibrosis, cirrhosis, and portal hypertension in infancy or childhood; however, ABCB4 mutations could be detected only in a subgroup of patients with this phenotype. (3,4) Adult patients carrying ABCB4 mutations were identified through screening of cohorts with unexplained cholestasis. (5) Patients with low phospholipid-associated cholelithiasis syndrome (LPAC) have been associated with (in most cases) heterozygous or less severe ABCB4 mutations. (6) ABCB4 mutations are also involved in intrahepatic cholestasis of pregnancy (ICP), in particular the subgroup of severe ICP with markedly elevated bile acid levels. (7-9)

The aim of this study was to provide national survey data on ABCB4 disease correlating genotypic information of homozygous or compound heterozygous carriers with features of the clinical and laboratory phenotype. In addition, we explored aspects of onset and course of ABCB4 deficiency. The results of the study illustrate not only the tremendous phenotypic spectrum of this disease but also pitfalls in differential diagnosis.

Patients and Methods

PATIENT RECRUITMENT

Due to the rare nature of mutations in the ABCB4 gene, cases with genetically proven ABCB4 gene mutations were systematically collected in a multicenter study with 10 participating hospitals in Germany. Patient files and electronic health care records of 38 patients, all of whom presented with one of the clinical phenotypes (PFIC3, ICP, or LPAC syndrome), were retrospectively reviewed. For further analysis, the patients were assigned to two groups according to age at clinical diagnosis: younger age (<18 years) or adults (≥18 years). Data were collected using a standardized questionnaire.

DATA COMPILATION

Systematic data collection was facilitated by a purpose-built electronic database. The following clinical parameters were documented: age at onset of symptoms of pruritus, jaundice, hepatomegaly, splenomegaly, liver cirrhosis, growth retardation, portal hypertension, and/or gallstones. Laboratory parameters collected at the first available documentation were alanine aminotransferase, aspartate aminotransferase, GGT, serum bilirubin, and bile acid concentrations. Age at genetic and clinical diagnosis was recorded as well as laboratory values at these time points.

OUTCOME AND TREATMENT

Outcome was analyzed regarding treatment with ursodeoxycholic acid (UDCA), rifampicin, or phenobarbital and was assessed by liver function tests and development of pruritus. A positive response to UDCA was defined as normalization of aminotransferase activities and total bilirubin; no improvement constituted a negative response. An intermediate response was defined as a reduction of liver enzymes without reaching normal values or with ongoing symptoms. Rifampicin
| Authors                  | No. | Age at Diagnosis (Onset) | Pruritus | Cholestasis | Hepatomegaly | Splenomegaly | Advanced Disease | Others                          | OLT (Age) |
|-------------------------|-----|--------------------------|----------|-------------|--------------|--------------|------------------|---------------------------------|-----------|
| de Vree et al. 1998     | 2   | 6 years, 9 years         | 2        | 2           | 2            |              | C (n = 2)        | Diarrhea, fever                 | 2         |
|                        |     | (3 months-8 months)      |          |             |              |              |                  |                                 |           |
| Jacquemin et al. 2001   | 3   | n.a.                     | 14       | 12          | 27           | 27           | PH (n = 2)       | Gallstones (n = 4)              | 18        |
|                        |     |                          |          |             |              |              |                  |                                 |           |
| Keitel et al. 2005      | 5   | n.a.                     | n.a.     | n.a.        | n.a.         | n.a.         | n.a.             | n.a.                           | 5         |
|                        |     | (birth -7 years)         |          |             |              |              |                  |                                 |           |
| Jung et al. 2001        | 16  | 2 months-11 years        | 14       | 12          | 1            |              | C (n = 13)       | Growth retardation (n = 9)      | 6         |
|                        |     |                          |          |             |              |              |                  | Gallstones (n = 4)              |           |
|                        |     |                          |          |             |              |              |                  | ICP (n = 3)                    |           |
| Englert et al. 2007     | 11  | 16-57 years              | n.a.     | 11          | n.a.         | n.a.         | C (n = 1)        | Gallstones, combination           | 1         |
|                        |     |                          |          |             |              |              |                  | with choreo-arthropathy           |           |
|                        |     |                          |          |             |              |              |                  | Gallstones (n = 3)              |           |
|                        |     |                          |          |             |              |              |                  |                                 |           |
| Crupi 2010              | 2   | birth-4 years            | 1        | n.a.        | n.a.         | n.a.         | n.a.             | Gallstones (n = 2)              | 0         |
|                        |     | (birth, 1 year)          |          |             |              |              |                  |                               |           |
| Anheim et al. 2010      | 1   | 40 years                 | n.a.     | 1           | n.a.         |              | C, PH            | Gallstones, combination           | 1         |
|                        |     | (17 years)               |          |             |              |              |                  | with choreo-arthropathy           |           |
| Dörk et al. 2010        | 3   | 13-n.a.                  | n.a.     | n.a.        | n.a.         | C (n = 1)    | Gallstones (n = 3) | Gallstones (n = 1)              | 0         |
| Matte et al. 2010       | 1   | 1.5 years                | n.a.     | 1           | n.a.         |              | Gallstones (n = 2) | Gallstones (n = 1)              | 0         |
| Colombo et al. 2011     | 28  | n.a.                     | 14       | 12          | 14           |              | C (n = 15), PH   | Gallstones (n = 3),              | 5         |
|                        |     |                          |          |             |              |              |                  | gallstones (n = 1)              |           |
|                        |     |                          |          |             |              |              |                  | Growth retardation (n = 2),      |           |
|                        |     |                          |          |             |              |              |                  | gallstones (n = 2),              |           |
| Colombo et al. 2011     | 20  | 1-45 years               | 4        | 2           | 2            |              | C (n = 1), PH    | Gallstones (n = 2),              | 0         |
|                        |     | (-1 year-14 years)       |          |             |              |              |                  | CCa (n = 2)                    |           |
|                        |     |                          |          |             |              |              |                  | Growth retardation (n = 3)       |           |
|                        |     |                          |          |             |              |              |                  | Gallstones (n = 1)              |           |
|                        |     |                          |          |             |              |              |                  | Growth retardation (n = 5)       |           |
|                        |     |                          |          |             |              |              |                  | Gallstones (n = 1),              |           |
|                        |     |                          |          |             |              |              |                  | ICP (n = 41)                   |           |
|                        |     |                          |          |             |              |              |                  | intrahepatic CCa (n = 1),        |           |
|                        |     |                          |          |             |              |              |                  | LPAC (n = 75)                  |           |
|                        |     |                          |          |             |              |              |                  | Liver failure (n = 1)            | 2         |
| Giovannoni et al. 2011  | 2   | 5 years, 9 years         | n.a.     | 2           | 1            | 1            | C (n = 1)        | Gallstones (n = 2),              | 0         |
|                        |     | (3 years, 4 years)       |          |             |              |              |                  | CCa (n = 2)                    |           |
|                        |     |                          |          |             |              |              |                  | Growth retardation              | 0         |
|                        |     |                          |          |             |              |              |                  | Gallstones (n = 2)              |           |
| Schüdek et al. 2012     | 1   | n.a.                     | n.a.     | n.a.        | n.a.         |              | Gallstones (n = 2) | Gallstones (n = 1),              | 0         |
|                        |     |                          |          |             |              |              |                  | CCa (n = 2)                    |           |
|                        |     |                          |          |             |              |              |                  | Growth retardation (n = 5)       |           |
| Tougeron et al. 2012    | 2   | 23-55 years              | 2        | 4           | n.a.         |              | PH (n = 1)       | Gallstones (n = 2)              | 0         |
|                        |     | (13-55 years)            |          |             |              |              |                  |                               |           |
| Fang et al. 2012        | 1   | 3                        | 3        | 3           | 3            | 3            | C (n = 1), PH    | Gallstones (n = 1),              | 0         |
|                        |     |                          |          |             |              |              |                  | CCa (n = 2)                    |           |
|                        |     |                          |          |             |              |              |                  | Growth retardation              | 0         |
| Anzivino et al. 2013    | 5   | 1 month-4.5 years        | 5        | 5           | n.a.         | n.a.         | C (n = 1)        | Gallstones (n = 1),              | 5         |
|                        |     | pregnant women           |          |             |              |              |                  | Gallstones (n = 1),              |           |
|                        |     |                          |          |             |              |              |                  | ICP (n = 5)                     |           |
| Poumon et al. 2013      | 21  | n.a.                     | n.a.     | n.a.        | n.a.         |              | Gallstones (n = 1), | Gallstones (n = 1),              | 0         |
|                        |     | (20-34 years)            |          |             |              |              |                  | CCa (n = 2)                    |           |
|                        |     |                          |          |             |              |              |                  | ICP (n = 51)                   |           |
|                        |     |                          |          |             |              |              |                  | intrahepatic CCa (n = 1),        |           |
|                        |     |                          |          |             |              |              |                  | LPAC (n = 75)                  |           |
|                        |     |                          |          |             |              |              |                  | Liver failure (n = 1)            | 2         |

*Heterozygous mutations; †patients of same family; ‡compound heterozygous; §in brackets: age at onset; §§genetics performed only in 12 patients; ‰genetics performed only in 22 patients; ††mostly heterozygous variants.

Abbreviations: C, liver cirrhosis; CCa, cholangiocarcinoma; n.a., not applicable; No., number of patients; PH, portal hypertension.
and phenobarbital medication were regarded as effective if pruritus was absent or improving by patient or parental assessment (intermediate improvement). Age at listing for orthotopic liver transplantation (OLT), age at OLT, and outcome were also documented. Complications were collected as reported in patient files.

**ABCB4 GENE ANALYSIS**

All exons and exon–intron boundaries of the *ABCB4* gene were sequenced as described."^{10,11}\"

**STATISTICAL ANALYSIS AND INSTITUTIONAL BOARD APPROVAL**

Quantitative variables were expressed as median and range. We used Excel 2007 and Access (Microsoft Corporation, Redmond, WA) for data collection and IBM SPSS Statistics version 23 for calculations. The study was conducted according to the guidelines of the Declaration of Helsinki and was reviewed and approved by the local ethics committee of Hannover Medical School (1645-2012).

**Results**

Overall, 38 patients (17 males, 21 females, from 29 families) with homozygous or (compound) heterozygous mutations of the *ABCB4* gene were enrolled in this multicenter study. Twenty-six patients had been clinically diagnosed before the age of 18 years, and in 12 patients the diagnosis was established in adulthood.

**CLINICAL CHARACTERISTICS OF PATIENTS < 18 YEARS AT DIAGNOSIS OF ABCB4 DEFICIENCY**

To date, 24 of the 26 patients (92%) are alive and have a median age of 8.9 years (range, 1.9-25.3 years). The family background revealed consanguinity in six of 19 families. A history of gallstones could be recorded in first-degree relatives in three of 19 families, and ICP was reported by two mothers of the patients. In one family, the brother of a patient had died several years before due to transplant-related complications after OLT for liver disease of, at that time, unknown etiology. Due to lack of data, this relative was not included in this cohort.

An overview of the clinical characteristics is presented in Table 2. All patients developed pruritus, and 16 (61.5%) patients presented with jaundice. Hepatomegaly was observed in 22 (84.6%) and splenomegaly in 25 patients (96.1%). Other clinical signs of portal hypertension were described in 18 patients (69%). Gallstones at any time were detected in only 4 patients (15%). Detailed data of the onset of disease were available for 23 patients; for the 3 other patients, clinical and laboratory data were only available after the age of 4 and 8 years for two siblings and 1 patient died at the age of 2 years after OLT. The onset of disease in these 3 patients occurred much earlier, but a detailed disease course could not be reconstructed; thus, these 3 patients were excluded from all subsequent analyses. The median age at onset of symptoms was 0.4 year (range, 0.1-13.7 years). Pruritus appeared at a median age of 1.0 year (0.1-15.0 years), hepatomegaly at 0.7 year (0.1-13.3 years), and splenomegaly at 1.2 years (0.2-13.3 years). Of note, jaundice did not belong to the first symptoms; the median age for jaundice onset was 2.9 years (0.1-15.0 years). Disease progression, as indicated by signs of portal hypertension, appeared at about 6.5 years (0.4-15.0 years).

**Comorbidities**

None of the patients suffered from chronic diarrhea. Growth retardation was reported in 10 patients; reduced bone density was detected in 4 patients. Central nervous system involvement, mostly concentration disturbances, was reported by the parents of 9 patients. At the time of the study, 18 children were still attending kindergarten or elementary school. No child has gone on to higher education, while 2 children did attend a special needs school. A lower secondary school education was reported by 3 children, and comprehensive school education by 2 children.

**Laboratory Values**

The first laboratory values were determined at a median age of 0.85 year, (range, 0.1-14.6 years). The tests often revealed elevated liver enzymes, with median aspartate aminotransferase 130 U/L (range, 26-693 U/L), alanine aminotransferase 140 U/L (21-540 U/L), and GGT 197 U/L (10-535 U/L). GGT in the first blood sample was elevated in all but 1 patient, but GGT also fluctuated in many patients over time. Serum bilirubin concentrations were often low (median 20 μmol/L) but were elevated in 12 patients. At the time of diagnosis, only 7 patients had elevated serum bilirubin concentrations.
### TABLE 2. CLINICAL CHARACTERISTICS OF THE STUDY COHORT WITH *ABCB4* MUTATIONS

| Patients (Sex) | Age at Clinical Diagnosis | Phenotype | Jaundice | Cholelithiasis/Recurrence After CHE | Cirrhosis, Portal Hypertension | GGT ALT [U/L] | UDCA Treatment/Response | OLT (Age) | Family History |
|---------------|---------------------------|-----------|----------|-----------------------------------|-------------------------------|--------------|------------------------|-----------|-----------------|
| 1 (m)         | 5 months                  | PFIC3     | –        | –/n.a.                            | –                             | 308          | +/(-)                  | –         | brother of 6 & 12 |
| 2 (f)         | 7 months                  | PFIC3     | –        | –/n.a.                            | –                             | 166          | +/n.d.                 | –         | –               |
| 3 (m)         | 8 months                  | PFIC3     | +        | –/n.a.                            | 82                            | 210          | +/-                   | 2 years 6 months | –               |
| 4 (m)         | 9 months                  | PFIC3     | +        | –/n.a.                            | 183                           | 124          | +/(-)                  | 1 year 3 months | –               |
| 5 (f)         | 11 months                 | PFIC3     | +        | –/n.a.                            | n.d.                          | 309          | +/-                   | 3 months     | –               |
| 6 (f)         | 11.5 months               | PFIC3     | –        | +/- n.a.                          | 183                           | 124          | +/-                   | –         | sister of 1 & 12 |
| 7 (m)         | 11.6 months               | PFIC3     | +        | –/n.a.                            | 81                            | 69           | +/-                   | –         | –               |
| 8 (f)         | 1 year 6 months           | PFIC3     | –        | –/n.a.                            | 232                           | 140          | +/-                   | –         | cousin of 16 & 17 |
| 9 (f)         | 1 year 6 months           | PFIC3     | +        | –/n.a.                            | 34                            | 39           | +/-                   | 11 years 6 months | sister of 15 |
| 10 (m)        | 1 year 9 months           | PFIC3     | +        | –/n.a.                            | 168                           | 290          | +/-                   | 8 years 10 months | brother of 14 |
| 11 (m)        | 1 year 10 months          | PFIC3     | +        | –/n.a.                            | n.d.                          | 577          | +/-                   | –         | sister of 1 & 6  |
| 12 (f)        | 2 years 2 months          | PFIC3     | –        | –/n.a.                            | 8                             | 17           | +/-                   | –         | –               |
| 13 (f)        | 2 years 6 months          | PFIC3     | –        | –/n.a.                            | 228                           | 194          | +/-                   | 5 years 10 months | sister of 10 |
| 14 (f)        | 2 years 8 months          | PFIC3     | +        | –/n.a.                            | 92                            | 41           | +/-                   | 13 years 2 months | brother of 9  |
| 15 (m)        | 3 years 3 months          | PFIC3     | +        | –/n.a.                            | 92                            | 106          | +/-                   | –         | brother of 17   |
| 16 (m)        | 3 years 7 months          | PFIC3     | –        | –/n.a.                            | 258                           | 300          | +/-                   | –         | sister of 16   |
| 17 (f)        | 3 years 7 months          | PFIC3     | –        | –/n.a.                            | 98                            | 123          | +/-                   | 4 years 7 months | –               |
| 18 (m)        | 2 years 1 month           | PFIC3     | +        | –/n.a.                            | 8                             | 8            | +/-                   | –         | –               |
| 19 (f)        | 5 years                   | PFIC3     | +        | +/- n.a.                          | 20                            | 20           | +/-                   | –         | –               |
| 20 (m)        | 6 years                   | PFIC3     | +        | –/n.a.                            | 309                           | 164          | +/-                   | 6 years 7 months | –               |
| 21 (f)        | 6 years 2 months          | PFIC3     | +        | –/n.a.                            | 139                           | 139          | +/-                   | –         | –               |
| Patients (Sex) | Age at Clinical Diagnosis | Phenotype | Jaundice | Cholelithiasis/Recurrence After CHE | Cirrhosis, Portal Hypertension | GST ALT [U/L] | UDCA Treatment/Response | OLT (Age) | Family History |
|----------------|---------------------------|-----------|----------|----------------------------------|--------------------------------|---------------|-------------------------|-----------|----------------|
| 22 (f)         | 9 years 9 months          | PFIC3     | +        | n.a.                             | +                              | 116           | +/(+)                   | 11 years 10 months | sister of 24 |
| 23 (f)         | 13 years 8 months         | PFIC3     | -        | +/n.a.                           | +                              | 146           | -/n.a.                  | n.d.       | on list sister of 25 |
| 24 (m)         | 13 years 10 months        | PFIC3     | +        | -/n.a.                           | +                              | 244           | -/n.a.                  | 16 years 1 month | brother of 22 |
| 25 (f)         | 14 years 8 months         | PFIC3     | -        | -/n.a.                           | +                              | 268           | +/(+)                   | 16 years    | sister of 23 |
| 26 (m)         | 15 years                 | PFIC3     | +        | +/n.a.                           | +                              | 288           | +/(+)                   | -          | -               |

Patients >18 years at clinical diagnosis of ABCB4 deficiency

| Patients (Sex) | Age at Clinical Diagnosis | Phenotype | Jaundice | Cholelithiasis/Recurrence After CHE | Cirrhosis, Portal Hypertension | GST ALT [U/L] | UDCA Treatment/Response | OLT (Age) | Family History |
|----------------|---------------------------|-----------|----------|----------------------------------|--------------------------------|---------------|-------------------------|-----------|----------------|
| 27 (m)         | 19 years 3 months         | PFIC3     | -        | +/n.a.                           | +                              | 428           | +/(+)                   | -          | brother of 28 |
| 28 (f)         | 19 years 10 months        | PFIC3     | -        | +/n.a.                           | -                              | 24            | +/(+)                   | -          | sister of 27 |
| 29 (f)         | 20 years 5 months         | PFIC3     | -        | +/n.a.                           | -                              | 78            | +/+                     | -          | -              |
| 30 (f)         | 21 years 5 months         | PFIC3     | +        | -/n.a.                           | -                              | 156           | -/n.a.                  | -          | sister of 31 |
| 31 (m)         | 21 years 10 months        | PFIC3     | -        | -/n.a.                           | -                              | 122           | -/n.a.                  | -          | brother of 30 |
| 32 (f)         | 26 years 7 months         | ICP       | +        | +/-                             | -                              | 27            | +/-                     | -          | -              |
| 33 (f)         | 29 years 2 months         | ICP       | +        | +/-                             | -                              | 1540          | +/(+)                   | -          | -              |
| 34 (f)         | 35 years 3 months         | LPAC      | -        | +/-                             | -                              | 545           | +/(+)                   | -          | -              |
| 35 (m)         | 36 years 7 months         | Bile duct stones | +       | +/-                             | -                              | 67            | +/-                     | -          | -              |
| 36 (m)         | 37 years 2 months         | LPAC      | +        | +/-                             | -                              | 74            | +/(+)                   | -          | -              |
| 37 (m)         | 38 years 7 months         | LPAC      | -        | +/-                             | -                              | 38            | n.d./n.d.               | -          | -              |
| 38 (f)         | 40 years 8 months         | LPAC      | +        | +/-                             | -                              | 217           | +/(+)                   | -          | -              |

*recurrent microlithiasis; "-", no or no response; "+", yes or full response; "(+)", partial response.

Abbreviations: ALT, alanine aminotransferase (values at time of genetic diagnosis); CHE, cholecystectomy; (f), female; GGT, γ-glutamyltransferase (values at time of genetic diagnosis); (m), male; n.a., not applicable; n.d., no data.
There is a period of latency between the onset of symptoms and diagnosis. The onset of disease occurred at a median age of 0.4 year (range, 0.1-13.7 years), and the median age at genetic diagnosis was 4.8 years (0.6-23.5 years). Clinical diagnosis followed symptoms 1.6 years (0-4.9 years) later. Diagnosis was delayed by 1 year when considering only the index patients and not the second affected child in the families.

In the 13 patients who required a liver transplant, 8 patients were previously suspected incorrectly of having other diseases, among them 3 patients with a diagnosis of biliary atresia leading to a Kasai operation in all 3; 1 patient with suspected Alagille syndrome; 1 patient with presumed PFIC1, who underwent a biliary diversion; 1 patient diagnosed with primary biliary cholangitis; and 2 patients with presumed viral infection (cytomegalovirus, Epstein-Barr virus).

**Therapy**

In total, 24 patients received UDCA treatment (doses of 11-30 mg/kg body weight per day). The effect of therapy was judged as intermediate in 17 children; 4 patients showed no response to UDCA. Additional treatment of pruritus was initiated in 9 children, using rifampicin (n = 7) and phenobarbital (n = 6). Rifampicin (4-11 mg/kg/day) seemed to stop in 2 patients or ameliorate pruritus in 3 patients. Phenobarbital was not as effective in the cohort, with 4 patients reporting no benefit and 1 patient describing intermediate benefit.

With progression of disease, 16 out of 26 children were listed for liver transplantation at a median age of 6.8 years. Thirteen patients underwent liver transplantation 4.2 years (range, 0.5-12.9 years) after the onset of symptoms at a median age of 6.9 years (0.6-16.1 years); among those, 6 patients split liver transplants. The indications for OLT were severe liver failure and pruritus. Of the children having a liver transplant, 2 died due to OLT-related complications (sepsis and primary graft failure). Acute biopsy-proven rejection was observed in 4 patients, and biliary complications occurred in 2 patients (bilioma, revision of biliodigestive anastomosis).

CLINICAL CHARACTERISTICS OF PATIENTS ≥18 YEARS AT DIAGNOSIS OF ABCB4 DEFICIENCY

In 12 patients of the study cohort, the diagnosis of ABCB4 deficiency was made in adulthood. An overview of their clinical characteristics is provided in Table 2.

The 12 patients originate from 10 different families. Five of these 12 patients presented with biliary fibrosis and/or cirrhosis corresponding to (non)cirrhotic PFIC3. The PFIC3 phenotype of these patients was generally less severe than in patients <18 years with diagnosis of ABCB4 deficiency. Only 1 patient had symptoms of portal hypertension, namely esophageal varices grade I without a bleeding episode. One patient also developed LPAC syndrome. Liver transplantation was not necessary in these patients. Four patients presented with LPAC syndrome, which was defined by at least two of the following features: age ≤40 years at the first onset of biliary symptoms; intrahepatic hypechoic foci, sludge, or microlithiasis; recurrence of biliary symptoms after cholecystectomy. Two patients were clinically diagnosed with ICP. One patient had recurrent gallstones within the common bile duct, which were repeatedly extracted by endoscopic retrograde cholangiopancreatography. In total, gallstones were found in 8 of the 12 patients (67%), and 6 of 12 patients (50%) had been jaundiced. GGT at the time of diagnosis was elevated in 9 of 12 patients (75%), with the median level being 139 U/L (range, 24-545 U/L).

UDCA therapy was conducted in 9 of 11 patients (81.8%; 1 patient had no available data). One patient with PFIC3 completely responded to therapy with normalization of laboratory parameters, and 2 patients with PFIC3 showed a partial response. Treatment in 1 of the patients with ICP resulted in a complete response while pregnant, and the second patient responded partially. For 3 of the 4 patients with LPAC, data were available, and all patients partially responded to UDCA therapy. In 1 of the patients with LPAC, only partial removal of intrahepatic bile duct stones was feasible despite multiple approaches by endoscopic retrograde cholangiopancreatography and percutaneous transhepatic cholangiography. Due to relapsing episodes of biliary pain and cholangitis, right-sided hepatectomy was carried out.

**ABCB4 GENE VARIANTS**

In total, all 38 patients were analyzed for ABCB4 variants. A detailed overview of the genetic characteristics is provided in Table 3.

In patients with disease onset before the age of 18 years, 20 different mutations were found. Patient number 18 was genetically diagnosed at an adult age, but severe disease manifestation, including OLT, occurred at an early age, so this patient was considered for
clinical and genetic evaluation in the pediatric cohort. In the majority of cases, the 20 different mutations, which were mainly homozygous, were missense mutations (n = 14) alongside one synonymous variant, one frameshift mutation, and four splicing defects.

In the 12 patients with clinical and genetic diagnosis at ≥18 years, ABCB4 gene sequencing revealed 12 distinct mutations. Compound heterozygous mutations were detected in 6 patients. Of the 12 mutations, mainly missense mutations were present (n = 10, 83.3%), along with one nonsense mutation leading to a premature stop of translation and one mutation leading to a splicing defect.

### Discussion

Because ABCB4 mutations and resulting phenotypes (PFIC3, LPAC, ICP) are rare, multicenter studies are necessary to gather data on the clinical course of these peculiar diseases. Epidemiologic data for PFIC3 do not exist. The estimated frequency according to an

| Patient | ABCB4 Variant 1 | ABCB4 Variant 2 |
|---------|----------------|-----------------|
|         | Location And Nucleotide Change | Predicted Effect | Status | Type | Location And Nucleotide Change | Predicted Effect | Status | Type |
| 1       | c.2177C>T     | p.Pro726Leu  | hom | missense | c.3486+5G>A | splicing variant | het | splicing |
| 2       | c.2166G>C     | p.Gly722Ala  | het | missense |
| 3       | c.1769G>A     | p.Arg590In   | hom | missense |
| 4       | c.1584G>C     | p.Glu528Asp | het | missense | c.1954A>G | p.Arg652Gly | het | missense |
| 5       | c.523A>G      | p.Thr175Ala  | het | missense | c.1954A>G | p.Arg652Gly | het | missense |
| 6       | c.2177C>T     | p.Pro726Leu  | hom | missense |
| 7       | c.67-68insAC  | p.Leu23His>"16" | het | frameshift | c.79A>G | p.Ser27Gly | het | missense |
| 8       | c.2177C>T     | p.Pro726Leu  | hom | missense |
| 9       | c.3633+1G>T   | splicing variant | het | splicing |
| 10      | c.2858C>A     | p.Ala953Asp  | hom | missense |
| 11      | c.2858C>A     | p.Ala953Asp  | hom | missense |
| 12      | c.2177C>T     | p.Pro726Leu  | hom | missense |
| 13      | c.266+1G>A    | splicing variant | het | splicing | c.3541C>G | p.Gln1181Glu | het | missense |
| 14      | c.2858C>A     | p.Ala953Asp  | hom | missense | c.504C>T | p.Asn168Asn | het | synonymous |
| 15      | c.3633+1G>T   | splicing variant | hom | splicing |
| 16      | c.2177C>T     | p.Pro726Leu  | hom | missense |
| 17      | c.2177C>T     | p.Pro726Leu  | hom | missense |
| 18      | c.2380G>C     | p.Ala794Pro  | hom | missense |
| 19      | c.504C>T      | p.Asn168Asn  | hom | synonymous |
| 20      | c.2783+1G>C   | splicing variant | hom | splicing |
| 21      | c.3257A>C     | p.Tyr1086Ser | hom | missense |
| 22      | c.283C>T      | p.Pro95Ser   | hom | missense |
| 23      | c.79A>G       | p.Ser27Gly   | het | missense | c.959C>T | p.Ser320Phe | het | missense |
| 24      | c.283C>T      | p.Pro95Ser   | hom | missense |
| 25      | c.79A>G       | p.Ser27Gly   | hom | missense | c.959C>T | p.Ser320Phe | het | missense |
| 26      | c.2950G>A     | p.Ala984Thr  | hom | missense |

Abbreviations: het, heterozygous; hom, homozygous.
Italian study group is 1:50,000. Only small cohorts of pediatric patients with PFIC3 have been published (Table 1). In earlier studies, not all patients were genetically tested as the first genetically identified patients date to the late 1990s. To date, more than 100 different ABCB4 mutations, reflecting the spectrum of disease, have been reported. In the present study, we were able to compile a cohort of 38 patients, all with genetically determined ABCB4 mutations, allowing us to provide an insight on the clinical course of the disease in pediatric patients and adults.

The pathophysiologic relevance is not clear for all ABCB4 variants. A minor allele frequency of >10% of the variant p.R652G suggests no pathogenicity, but the clinical presentation of patients 4 and 5 with at least one pathogenic variant indicates a pathogenic effect of this variant. It cannot be ruled out that another complex variant has been missed or that functional effects occur in combination with other variants. Additionally, there is only limited knowledge on alternative splicing of ABCB4 and its functional relevance. Further functional analyses are needed to address these questions. Factors or modifiers responsible for symptoms in heterozygous carriers are unknown. There might be an underrepresentation of heterozygotes due to the broad disease spectrum not leading to medical contact in a subgroup of these individuals.

Of note, in the pediatric patients, 9 children were initially misdiagnosed as having other cholestatic diseases and 7 underwent transplantation. These incorrect diagnoses might have been due to a delay in genetic diagnosis as testing of ABCB4 variants was performed in the pediatric patients more than 4 years (median) after initial clinical symptoms. Fluctuating activities of transaminases and even normal GGT or bilirubin levels might contribute to the delay in correct diagnosis. Young patients of the cohort were misdiagnosed with biliary atresia as a common differential diagnosis at this age, but no obvious risk factors could be identified. Similarly, Wilson disease has been misdiagnosed at an older age. These findings illustrate the need for increased awareness for ABCB4 disease in different age groups combined with broadened diagnostic strategies.

Cognitive development disorders have not been described in patients with PFIC3. Although no higher education was reported in our pediatric cohort, statistic confounders and the patient’s young age or socioeconomic background must be considered. Children surviving liver transplantation are at risk of prolonged cognitive and academic deficits.

Patients with an initial diagnosis of ABCB4 disease in adulthood may display a clinical phenotype with a later onset, such as ICP; alternatively, clinical or laboratory signs of the disease could have been misinterpreted or overlooked. These patients typically present with a heterogeneous clinical picture. In the series, the phenotypic presentation ranged from ICP and LPAC syndrome to (non)cirrhotic PFIC3. In the study, ABCB4 mutations were all heterozygous in these patients, a finding that has also been reported in previous series; however, some patients may have homozygous mutations. Genetic analysis in patients with cryptogenic cirrhosis might lead to detection of ABCB4 mutations. Of interest, genetic analysis in 1 of 2 siblings (patients 27 and 28) revealed the same compound heterozygous mutations, whereas the clinical PFIC3 phenotype was more severe in the male patient. This finding points to the impact of further disease modifiers, such as genetic variants of other hepatocanicular transporter genes, hormones, or environmental factors.

As a treatment strategy, UDCA has been used in most patients soon after diagnosis. UDCA is more hydrophilic and less hepatotoxic compared to the primary bile acids, competes with them for re-uptake in the intestine, and suppresses their de novo synthesis. The response rate to UDCA was satisfactory in PFIC3 patients but mostly with an intermediate response. For pruritus relief in 9 children, additional drugs had to be used. When the outcome of UDCA and rifampicin/phenobarbital was unsuccessful, children usually progressed to end-stage liver disease and were assessed for OLT. In fact, the majority of children were listed for OLT; and children frequently had a liver transplant within the first decade of life even when initial symptomatic response to UDCA was noted. In the group with a diagnosis of ABCB4 deficiency in childhood, the combination of medical and surgical therapies resulted in 92% of patients being alive at a median age of 8.9 years. However, current medical therapy is not satisfactory for the majority of patients in the long term. Only recently, cell culture-based studies demonstrated that a disturbed ABCB4 function in selected missense variants leading to defective membrane trafficking can be restored by treatment with chaperone drugs. In the series, the vast majority of patients harbored missense mutations. These data support the relevance of further functional studies of ABCB4 variants and early genetic testing to provide specific individualized medical therapy in the future to prevent development of cirrhosis.
An increased risk for hepatic malignancies has been reported in adult patients with PFIC (32) in particular, in ABCB4 gene mutations and cholangiocarcinoma. (33) No malignancy has been reported so far in our cohort, but prospective follow-up is necessary to determine and monitor the carcinoma risk.

One of the limitations of the present study is that data could only be gathered retrospectively from different hospitals. Moreover, histopathologic changes were not assessed systematically due to the heterogeneity of biopsy sampling at different time points, when performed, reflecting various stages of disease progression. Despite the retrospective and multicenter nature of this study, its strength is the large number of patients who were included and treated successfully.

This series highlights the severe and early manifestation of PFIC3 that leads to the necessity of liver transplantation in almost 50% of patients, frequently in the first decade of life. When clinical onset of symptoms in ABCB4 deficiency appear in adulthood, the clinical phenotype and genetic alterations are generally less severe; however, the clinical picture is variable, and patients may also present with liver cirrhosis and signs of portal hypertension or complex intrahepatic bile duct stones. Sometimes, even severe ABCB4 mutations become evident only in adults because they only affect one allele. To eliminate the reporting bias of retrospective analyses, more comprehensive clinical data and a longer follow-up in prospective studies are needed to establish genotype–phenotype correlations, which are suggested by functional analyses that relate clinical outcomes to the degree of phosphatidylcholine floppase activity. (15) Early genetic testing during the course of liver disease will be even more relevant in the future when individualized pharmacotherapy might become available for selected missense variants.

Acknowledgment: We thank all participating patients and families.

REFERENCES

1) Hori T, Nguyen JH, Uemoto S. Progressive familial intrahepatic cholestasis. Hepatobiliary Pancreat Dis Int 2010;9:570-578.
2) Sambrotta M, Stroutnieks S, Papouli E, Rushton P, Clark BE, Parry DA, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nutr Genet 2014;4;6:326-328.
3) Jacquemin E, De Vree JM, Creteil D, Sokal EM, Sturm E, Dunmont M, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001;120:1448-1458.
4) Chen HL, Chang PS, Hsu HC, Lee JH, Ni YH, Hsu HY, et al. Progressive familial intrahepatic cholestasis with high gamma-glutamyltransferase levels in Taiwanese infants: role of MDR3 gene defect? Pediatr Res 2001;50:50-55.
5) Zioli M, Barbu V, Rosmorduc O, Frassati-Biaggi A, Barget N, Hermelin B, et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008;135:131-141.
6) Poupon R, Rosmorduc O, Boelle PY, Chretien Y, Corpechot C, Chazouilleres O, et al. Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: a study of 156 consecutive patients. Hepatology 2013;58:1105-1110.
7) Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004;14:91-102.
8) Wasmuth GE, Glantz A, Kepper H, Simon E, Barts C, Rath W, et al. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. Gut 2007;56:265-270.
9) Jacquemin E, Creteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999;353:210-211.
10) Simon E. Genetic predisposition of the intrahepatic pregnancy cholestasis: mutation analysis of the phospholipid transporter ABCB4 and the bile acid export pump ABCB11. [Dissertation in German]. Aachen, Germany: RWTH Aachen University; 2005.
11) Zimmer V, Krawczyk M, Mahler M, Weber SN, Mullenbach R, Lammert F. Severe hepatocellular dysfunction in obstetric cholestasis related to combined genetic variation in hepatobiliary transporters. Clin Exp Obstet Gynecol 2012;39:32-35.
12) Degiorgio D, Colombo C, Seia M, Porcaro L, Costantino L, Zazzeron L, et al. Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). Eur J Hum Genet 2007;15:1230-1238.
13) Fang Lj, Wang XH, Knisely AS, Yu H, Lu Y, Liu LY, et al. Chinese children with chronic intrahepatic cholestasis and high gamma-glutamyl transpeptidase: clinical features and association with ABCB4 mutations. J Pediatr Gastroenterol Nutr 2012;55:150-156.
14) Colombo C, Vajro P, Degiorgio D, Coviello DA, Costantino L, Tornillo L, et al. Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations. J Pediatr Gastroenterol Nutr 2011;52:73-83.
15) Gordo-Gilart R, Andueza S, Hierro L, Martinez-Fernandez P, D’Agostino D, Jara P, et al. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity. Gut 2015;64:147-155.
16) Gordo-Gilart R, Hierro L, Andueza S, Munoz-Bartolo G, Lopez C, Diaz C, et al. Heterozygous ABCB4 mutations in children with cholestatic liver disease. Liver Int 2016;36:258-267.
17) Lee WS, Chai PF, Looi LM. Progressive familial intrahepatic cholestasis in Malaysian patients--a report of five cases. Med J Malaysia 2009;64:216-219.
23) Droge C, Bonus M, Baumann U, Klindt C, Lainka E, Gotthardt D, Runz H, Keitel V, Fischer C, Flechtenmacher C, Sturm E, Cresteil D, Bosma PJ, Aten J, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 1998;95:282-287.

22) Cooper DN, Ball EV, Stenson PD, Phillips AD, Evans K, Heywood S, et al. The Human Gene Mutation Database. http://www.hgmd.org. Accessed August 2017.

21) Jacquemin E. Progressive familial intrahepatic cholestasis. J Gastroenterol Hepatol 2001;16:134-146.

20) Englert C, Grabhorn E, Richter A, Rogiers X, Burdelski M, Keitel V, Burdelski M, Warskulat U, Kuhl Kamp T, Keppler D, Haussinger D, et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2003;41:1160-1172.

19) Jung C, Driancourt C, Bausan C, Zater M, Hadchouel M, Meunier-Rotival M, et al. Prenatal molecular diagnosis of inherited cholestatic diseases. J Pediatr Gastroenterol Nutr 2007;44:453-458.

18) Aydogdu S, Cakir M, Arikan C, Tumgor G, Yukeukaya HA, Yilmaz F, et al. Liver transplantation for progressive familial intrahepatic cholestasis: clinical and histopathological findings, outcome and impact on growth. Pediatr Transplant 2007;11:634-640.

17) Crupi I. Progressive familial intrahepatic cholestasis (PFIC) type 3 in two Sicilian siblings of nonconsanguineous parents. Scientific World Journal 2010;10:1065-1066.

16) Anheim M, Chamouard P, Rudolf G, Ellero B, Vercesi L, Goichot B, et al. Unexpected combination of inherited chorea-acanthocytosis with MDR3 (ABCB4) defect mimicking Wilson’s disease. Clin Genet 2010;78:294-295.

15) Denk GU, Bikker H, Lekanne Dit Deprez RH, Terpstra V, van der Loos C, Beuers U, et al. ABCB4 deficiency: a family saga of undefined etiology. J Pediatr Gastroenterol Nutr 2010;51:488-493.

14) Kubitz R, Bode J, Erhardt A, Graf D, Kircheis G, Muller-Stover I, et al. Cholestatic liver diseases from child to adult: the diversity of MDR3 disease. Z Gastroenterol 2011;49:728-736.

13) Giovannoni I, Santorelli FM, Candusso M, Di Rocco M, Bellaccio E, Callea F, et al. Two novel mutations in African and Asian children with progressive familial intrahepatic cholestasis type 3. Dig Liver Dis 2011;43:567-570.

12) Schukfeh N, Metzelder ML, Petersen C, Reismann M, Pfister ED, Ure BM, et al. Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis. J Pediatr Surg 2012;47:501-505.

11) Anzivino C, Odoardi MR, Meschiari E, Baldelli E, Facchinetti F, Neri I, et al. ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population. Dig Liver Dis 2013;45:226-232.

10) Giovannoni I, Callea F, Bellaccio E, Torre G, De Ville De Goyet J, Franchalaci P. Genetics and molecular modeling of new mutations of familial intrahepatic cholestasis in a single Italian center. PLoS One 2015;10:e0145021.

Author names in bold designate shared co-first authorship.